United Therapeutics Q4 GAAP EPS $4.36 Beats $4.19 Estimate, Sales $614.70M Beat $575.87M Estimate
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics (NASDAQ:UTHR) reported Q4 GAAP EPS of $4.36, surpassing the $4.19 estimate, marking a 63.3% increase from last year. Sales reached $614.70M, exceeding the $575.87M estimate, a 25.07% increase from the previous year.
February 21, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics reported a strong Q4 with earnings and sales surpassing estimates, indicating robust financial health and growth.
The significant beat on both earnings per share (EPS) and sales estimates, coupled with substantial year-over-year growth, suggests a strong financial performance and positive outlook for United Therapeutics. This is likely to instill investor confidence and could lead to a short-term uptick in UTHR's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100